PT-141: a melanocortin agonist that works on desire rather than plumbing
Every other drug in this category works on blood flow. This one works in the brain, which is why it does something different and why its side effects are different too.
- Also known as
- Bremelanotide, Vyleesi
- Class
- Sexual health peptide
- Regulatory status
- FDA APPROVED for female HSDD (Vyleesi). Off-label for male sexual dysfunction.
- Modelled half-life
- 2.7 h
- Time to peak
- 1 h
- Formulation
- Aqueous (reconstituted powder)
- Before mixing
- Sealed powder tolerates room temperature in transit, but keep it refrigerated at 2–8 °C (36–46 °F) for anything beyond a few weeks, or frozen for months. Keep it dark — the carton it shipped in is doing a job.
- After mixing
- Once reconstituted with bacteriostatic water: refrigerate at 2–8 °C and use within about 28 days. The benzyl alcohol in bacteriostatic water is what buys that window — plain sterile water has no preservative, so a vial mixed with it should be treated as one sitting only. Kits are usually ten vials: only the one you mixed is on that 28-day clock — the sealed ones keep their own, much longer shelf life, so store them as powder, not as solution.
- What ruins it
- Do not freeze a reconstituted vial. Repeated freeze–thaw is one of the more reliable ways to degrade a peptide.
- Handling caveat
- General handling practice for this formulation. Your supplier’s own insert or COA overrides anything here.
A completely different target
Established clinical use PDE5 inhibitors act peripherally: they prevent the breakdown of cyclic GMP in vascular smooth muscle, so an erection that has been initiated is sustained. They do nothing about whether the signal to initiate one arrives. Bremelanotide is a melanocortin receptor agonist acting in the central nervous system, principally at MC4R in the hypothalamus, on the circuitry that generates sexual desire and arousal in the first place. It is a fragment of the alpha-MSH family rather than anything related to testosterone.
That is why the two are not substitutes and why bremelanotide has been studied in people for whom PDE5 inhibitors did not work: they address different steps. It is also why it is taken before an occasion rather than daily — the app models a half-life under three hours, and the effect is an episode rather than a background state.
The approval is real but narrow: it is approved for hypoactive sexual desire disorder in premenopausal women. Off-label or community practice Use in men is off-label, and it has been studied reasonably extensively in that population without an approval following. That is a meaningful distinction to hold on to when reading confident claims about it.
Nausea is the effect that decides the dose
Nausea is the most common adverse effect and it is dose-related, sometimes severe, and it is the reason the dosing rows the app records start low. Melanocortin receptors are expressed in brainstem regions involved in emesis, so this is mechanism rather than an idiosyncrasy. Flushing and a transient rise in blood pressure with a small fall in heart rate are the other consistent findings, which is why the approved labelling excludes people with uncontrolled hypertension or established cardiovascular disease.
Off-label or community practice Hyperpigmentation is the effect that turns up with repeated use rather than with a single dose, and it comes from MC1R activity — the same receptor that drives tanning. Darkening of the face, gums and existing naevi has been reported. A moleprogression that would be worth a dermatologist’s attention is exactly the thing this drug can also cause benignly, which is an argument for a baseline skin check rather than a reason for alarm.
What it is not
It is not a testosterone substitute and it does not treat low testosterone. Someone whose libido has fallen because their testosterone has fallen is being offered a drug that bypasses the question rather than answering it, and the useful order of operations is to measure first. The free versus total testosterone page covers what to measure and why the two can move differently.
It is also not a treatment for the many non-hormonal causes of low desire — relationship context, depression, medication side effects, sleep debt, alcohol. A drug that acts on the desire circuit will produce an effect regardless of why desire was low, and that is not the same as it being the right intervention.
Nitrates are the one hard contraindication worth stating on a page: the blood-pressure effect makes that combination dangerous. Everything else here — whether it applies, at what amount, alongside what else — is a prescribing decision, and any effect from the list below belongs with the clinician who prescribed it.
How long one dose lasts
pkCurve function.
The vertical axis is relative: the shape carries across people, the absolute
concentration does not.Try other intervals on the half-life and steady-state calculator, which runs the same function against whatever cadence you type.
The dosing rows the app records
Established clinical use Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.
| Label | Amount | Route and frequency | Duration recorded |
|---|---|---|---|
| Male Sexual Dysfunction | 1-2mg | SubQ 30-60 min before activity | As needed — not daily use |
| Female (FDA approved) | 1.75mg | SubQ 45 min before activity | As needed |
| Starting Dose | 0.5mg | SubQ injection 45 min before | As needed |
| Standard | 1.75mg | SubQ injection 45 min before | Max 1x per 24 hours |
| High Response | 1mg | SubQ injection 45 min before | Titrate based on response |
What the app monitors alongside it
The panel below is the app’s own monitoring note for PT-141, verbatim. None of the analytes it names has a page here yet.
- Monitoring panel
- Blood pressure before and after first dose, nausea severity tracking, skin hyperpigmentation assessment with long-term use.
Drawbacks and risks the app records
From the app’s own entry. The nausea item is not a footnote — it is the effect that most often ends use, and it is predictable from the mechanism.
- Nausea is the primary side effect — can be significant
- Transient blood pressure increase
- Flushing and facial warmth
- Not FDA approved for men (though extensively studied)
- Cost — not typically covered by insurance for men
- Injection only (SubQ)
- Nausea is common especially first use
- Cannot use with nitrates
- Expensive
- Facial flushing and hyperpigmentation with repeated use
Interaction rules that name PT-141
From the app’s interaction data, filtered so no rule naming a compound this site does not publish appears. Not exhaustive, and not a safety clearance: a combination that is not listed is one nobody has documented here, which is not the same as one that is fine. The combination checker has the rest.
MT-2 and PT-141 — Overlap in Mechanism
MT-2 and PT-141 (bremelanotide) both activate MC4R for sexual function enhancement. They overlap significantly in mechanism. Using both simultaneously provides little additional benefit and increases side effect risk (nausea, flushing, blood pressure elevation). Use one at a time.
What to watch: Blood pressure (both cause transient elevation), nausea assessment.
Questions people actually ask
Can it be combined with a PDE5 inhibitor?
They act at different steps and the combination is described in practice. Both affect blood pressure, which is the reason that decision belongs with a prescriber who knows your cardiovascular history rather than with a page.
Why does it cause tanning?
Because MC1R — the melanocortin receptor that controls melanin production — is one of the receptors it activates. That is the same mechanism the tanning peptides use, and it is why hyperpigmentation shows up with repeated dosing.
Is the female approval evidence for the male use?
Partly, and only partly. It establishes the mechanism works in people and gives a real safety database. The male trials were run and did not result in an approval, which is information in itself. Off-label means off-label.
How long does it last?
The app models a half-life under three hours, and the dosing rows describe taking it forty-five minutes or so beforehand. The subjective effect is reported as outlasting the peptide, which is what you would expect from something acting on a signalling circuit rather than on a muscle.
Where the load-bearing numbers come from
Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.
- Central melanocortin mechanism versus peripheral PDE5 inhibition
- The bremelanotide pharmacology literature and the approved labelling for the female indication
- Nausea, blood pressure and hyperpigmentation
- The phase III programme for hypoactive sexual desire disorder, reported 2019
- Approved indication
- The approval string in the fact box is app.html’s own field, reproduced verbatim
- Modelled half-life and time to peak
- app.html’s TL_PK entry
An as-needed compound is the easiest one to lose track of. TherapyLog records what you took and when, so a pattern is visible rather than remembered.
Save this dose to your log